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Fibroblasts are the most common cell type of the connective tissues found throughout the
body and the principal source of the extensive extracellular matrix (ECM) characteristic of
these tissues. They are also the central mediators of the pathological fibrotic accumulation
of ECM and the cellular proliferation and differentiation that occurs in response to
prolonged tissue injury and chronic inflammation. The transformation of the fibroblast cell
lineage involves classical developmental signaling programs and includes a surprisingly
diverse range of precursor cell types—most notably, myofibroblasts that are the apex of
the fibrotic phenotype. Myofibroblasts display exaggerated ECM production; constitutively
secrete and are hypersensitive to chemical signals such as cytokines, chemokines, and
growth factors; and are endowed with a contractile apparatus allowing them to manipulate
the ECM fibers physically to close open wounds. In addition to ECM production,
fibroblasts have multiple concomitant biological roles, such as in wound healing,
inflammation, and angiogenesis, which are each interwoven with the process of fibrosis.
We now recognize many common fibroblast-related features across various physiological
and pathological protracted processes. Indeed, a new appreciation has emerged for
the role of non-cancerous fibroblast interactions with tumors in cancer progression.
Although the predominant current clinical treatments of fibrosis involve non-specific
immunosuppressive and anti-proliferative drugs, a variety of potential therapies under
investigation specifically target fibroblast biology.
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INTRODUCTION
Fibroblasts are the workhorse of the most important tissue that
holds the human body together—connective tissue. Connective
tissue joins and supports all other tissues, including the parenchy-
mal tissues of organs. This connective tissue is made of fibroblasts
widely-spaced in a vast extracellular matrix (ECM) of fibrous
proteins and gelatinous ground substance. Fibroblasts produce
the ECM’s structural proteins (e.g., fibrous collagen and elastin),
adhesive proteins (e.g., laminin and fibronectin), and ground
substance (e.g., glycosaminoglycans, such as hyaluronan and gly-
coproteins). However, fibroblasts also play various additional
roles beyond ECMproduction. For example, fibroblasts serve piv-
otal roles in ECMmaintenance and reabsorption, wound healing,
inflammation, angiogenesis, cancer progression, and in physio-
logical as well as pathological tissue fibrosis. Ancillary to these
various biological roles, fibroblasts produce and respond to a
broad array of paracrine and autocrine signals, such as cytokines
and growth factors. Targeting these ancillary signaling events is
the main strategy underlying multiple lines of research for a new
generation of treatments for fibroblast-related disorders.
Fibroblasts are mesenchymal cells derived from the embryonic
mesoderm tissue, and they are not terminally differentiated. They
can be activated by a variety of chemical signals that promote
proliferation and cellular differentiation to form myofibroblasts
with an up-regulated rate of matrix production. Fibroblast acti-
vation plays a vital role in wound healing however, in some cases
and for reasons that remain to be fully elucidated, their activation
becomes uncontrolled, producing a pathological fibrotic response
that promotes multiple diseases and affects a variety of organs.
Indeed, fibrosis plays a significant contributory role in most cases
of organ failure. Examples are wide ranging: systemic sclerosis
(SSc); idiopathic pulmonary fibrosis (IPF); liver cirrhosis; kidney
fibrosis; and the cardiac fibrosis observed in cardiac hypertrophy
resulting in heart failure. The essential role of fibroblasts in lung
fibrosis was validated using lineage-specific deletion of the type II
TGFβ receptor (Hoyles et al., 2011).
Here we review a variety of fibroblast functions that illustrate a
central role for fibroblasts in the pathology of fibrosis. We review
ECM production in relation to fibrosis, some examples of criti-
cal chemical signaling, myofibroblast differentiation, the role of
fibroblasts in stromal-cancer interactions, and potential clinical
therapies targeting fibroblasts.
FIBROBLAST ROLE IN MATRIX PRODUCTION AND
MAINTENANCE
Fibroblasts’ most well-known biological role is the production
of the rich ECM of connective tissues. Fibroblasts produce and
secrete all components of the ECM, including the structural pro-
teins, adhesive proteins, and a space-filling ground substance
composed of glycosaminoglycans and proteoglycans.
STRUCTURAL PROTEINS
Fibroblasts produce an interconnecting meshwork of extracellu-
lar protein fibers and connector proteins that provide structure
to tissue. Reciprocally, these proteins can promote the differen-
tiation of profibrotic myofibroblasts through positive feedback
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regulation during fibrosis (Blaauboer et al., 2013). The vari-
ety of ECM structures serve roles as diverse as forming lamina
that delineate borders separating distinct cell types with dif-
ferent functions, to serving as interstitial regions that connect
cells of a common type with a common biological function.
Fibroblasts provide these specialized ECMs in different tissues
by expressing and secreting a robust and variable repertoire of
structural proteins with distinct properties. For example, the fib-
ril rigidity provided by collagen type I, the most abundant protein
in mammals, is due to its rope-shaped, triple-stranded helical
tertiary protein structure that reinforces its tensile strength, pre-
venting overstretching. In contrast, elastin proteins form highly
crosslinked, yet unstructured, elastic networks that allow for
expansive stretching without breaking. Tissues requiring differ-
ing degrees of rigidity vs. flexibility, such as skin and lung, differ
in the relative expression of collagen subtype and elastin pro-
teins. Moreover, the pathological histology of fibrosis includes an
increase in the relative balance of collagen (Gilbane et al., 2013;
McKleroy et al., 2013). A large number of genes that express dif-
ferent collagen subtypes also provide unique matrix properties.
Fibroblast-mediated formation of basement membrane (com-
posed of a layer of basal lamina and a layer of reticular lamina)
serve as structural scaffolds critical for tissue regeneration in
wound healing; cell barriers segregating epithelial from endothe-
lial tissues; barriers preventing malignant escape or invasion of
cancerous cells; filtration devices found in the glomerular filtra-
tion of blood in the kidney; and filtration of the alveoli-capillary
interface in the lung. Basement membrane ECM is composed
largely of collagen type IV, and in this environment, the pres-
ence of collagen type I promotes the up-regulation of TGFβ
and epithelial-to-mesenchymal transdifferentiation (EMT), pro-
ducing, for example, fibroblasts with a profibrotic phenotype in
kidney fibrosis (Zeisberg et al., 2001).
ADHESIVE PROTEINS
Adhesive ECM proteins such as fibronectin and laminin form
the connection between cells and the ECM. Fibronectins bind
to ECM fibers and contain RGD domains required for interact-
ing with the integrin transmembrane cell adhesion proteins. It
is ironic that fibronectin is essential for collagen assembly into
ECM, yet a conditional knock out of fibronectin expression in
the liver was found to increase collagen production, TGFβ sig-
naling, and hepatic fibrosis (Kawelke et al., 2011). Therefore,
locally produced fibronectin in ECM also regulates the amount of
active TGFβ and serves to protect tissue from TGFβ hyperstimu-
lation (Kawelke et al., 2011). Laminins also interact with integrin
receptors to regulate cell attachment to the basal lamina. In fact,
laminin has been proposed as a biomarker for hepatic fibrosis
(Santos et al., 2005).
GROUND SUBSTANCE
The ground substance of ECM is a hydrated gel of proteo-
glycans that is interspersed among the structural proteins. The
ground substance forms a final pathway for nutrient flow
beyond the reach of blood vessel transport into tissues as well
as a pathway for intercellular communication. This cell-free
medium forms an avenue for cell migration of immune cells,
fibroblasts, and myofibroblasts. It is also an essential avenue for
endothelial cell migration during angiogenesis. The proteogly-
cans of ground substance are proteins that are posttranslationally
modified by the addition of unbranched polysaccharides called
glycosaminoglycans (GAGs), or descriptively as mucopolysac-
charides. These GAGs are composed of repeating disaccharide
units that contain an amino sugar of either N-acetylglucosamine
or N-acetylgalactosamine and are often sulphated. The family
of GAG posttranslational modifications found in ECM includes
hyaluronan (non-sulfated), heparin and heparan sulfate, chon-
droitin and dermatan sulfate, and keratan sulfate.
Proteoglycans directly interact with many chemical signals,
such as growth factors and TGFβ. Through these interactions,
the ECM proteoglycans can regulate chemical signaling by either
inhibiting or augmenting a signal’s responsiveness. The proteo-
glycan tenascin-C (TN-C) interacts with ECM (Chung et al.,
1995), cell surface receptors (Schnapp et al., 1995; Midwood
et al., 2009; De Laporte et al., 2013), and is secreted in response
to TGFβ stimulation (Pearson et al., 1988). TN-C is highly
expressed during embryonic development, chronic inflamma-
tion, and fibrosis. Our group has characterized the role of
insulin-like growth factor binding protein (IGFBP)-3, which is
overexpressed in fibrotic skin and lungs, in mediating the induc-
tion of TN-C by TGFβ (Brissett et al., 2012). Exposure of lung
fibroblasts in vitro to IGFBP-3 directly induces TN-C production
and secretion. Further, SSc patients with pulmonary fibrosis have
significantly higher levels of circulating TN-C compared with
SSc patients without pulmonary fibrosis (Brissett et al., 2012).
Another ECM proteoglycan, decorin, antagonizes TGFβ activ-
ity (Yamaguchi et al., 1990). Decorin is a small proteoglycan
that contains a single GAG chain of either chondroitin sulfate
or dermatan sulfate. Decorin directly interacts with TGFβ and
inhibits its profibrotic biological activity. Recombinant expres-
sion of decorin in the lung airways of mice inhibits bleomycin-
induced pulmonary fibrosis (Kolb et al., 2001). In addition to
the secreted proteoglycans of the ECM, there are also a number
of cell membrane proteoglycans that can interact with chemi-
cal signals and function as co-receptors. An important example
is the syndecans. Syndecan 2 (SDC2) is over-expressed during
fibrosis and is induced in fibroblasts in response to both TGFβ
and IGFBP-3 (Ruiz et al., 2012). Similar to the above exam-
ples, proteoglycans can also interact with membrane-bound and
secreted proteases such as MMP-7 (Yu and Woessner, 2000) as
well as secreted protease inhibitors such as TIMP-3 (Yu et al.,
2000), regulating their biological activities in signaling and ECM
processing.
ECMMAINTENANCE AND REABSORPTION
In addition to extracellular matrix production, fibroblasts are
also responsible for its maintenance and reabsorption. Unlike
bone, where a specialized cell type, osteoblasts, produces bone
(a highly mineralized extracellular matrix) and a distinct cell
type, osteoclasts, reabsorbs bone, there are no known fibrob-
last cells that specialize in matrix reabsorption. As far as we
know, the same fibroblasts that produce ECM are responsible
for matrix maintenance and degradation. As such, these cells
have important roles in resolving pathological fibrosis. Collagen
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maturation is controlled by the enzyme lysyl oxidase (Lox), which
is produced by fibroblasts, cross-links collagen fibers, and thereby
strengthens ECM. Interestingly, inhibiting LOX-mediated colla-
gen cross-linking antagonizes both fibrosis and tumor metastasis
(Cox et al., 2013). Collagen turnover (catabolism) is regulated by
a multitude of secreted extracellular proteases. Fibroblasts pro-
duce bothmatrix degrading enzymes (such as metalloproteinases,
aka MMPs) as well as their inhibitors (the tissue inhibitors of
metalloproteinases, aka TIMPs). Curiously, MMP expression in
IPF is increased, and experiments with various MMP knock-
out mice demonstrate protection from bleomcyin-induced lung
fibrosis (McKleroy et al., 2013).
CONCOMITANT AND INTERWOVEN BIOLOGICAL ROLES OF
FIBROBLASTS
WOUND HEALING
Fibroblasts have a pivotal role in wound healing in response to
tissue injury. First and foremost, fibroblasts respond to wound
healing by proliferating and by chemotaxing to the sites of tissue
injury to rebuild the ECM as a scaffold for tissue regeneration.
Fibroblast to myofibroblast transitioning enables the contraction
of the matrix to seal an open wound in the event of the loss of tis-
sue (Gabbiani, 2003;Midwood et al., 2004). Fibroblasts also play a
role in blood clotting, such as in the production of urokinase plas-
minogen activators (PAs) and their inhibitors (PAIs). Fibroblasts
express the protease activated receptor PAR1 that enables fibrob-
last responsiveness to activated thrombin. PAR1 receptor expres-
sion is upregulated in IPF (Howell et al., 2005) and in lung
tissue of SSc patients (Bogatkevich et al., 2005). Further, PAR1
knockout mice resist bleomycin-induced lung fibrosis (Howell
et al., 2005). PAR1 receptors have well documented roles in the
process of fibrosis, and PAR1 receptor antagonists as well as
thrombin inhibitors could be beneficial for treating SSc and IPF
(Atanelishvili et al., 2014).
INFLAMMATION
Fibroblasts serve roles in inflammation and immune cell recruit-
ment to sites of tissue injury. Furthermore, fibroblasts produce
and are responsive to many inflammatory cytokines. Fibroblasts
are responsive to cytokines such as TGFβ1, IL-1β, interleukin-
6 (IL-6), IL-13, IL-33 (Feghali and Wright, 1997; Scotton and
Chambers, 2007; Savinko et al., 2012), as well as prostaglandins
(Keerthisingam et al., 2001; Stratton et al., 2002; Maher et al.,
2010) and leukotrienes (Mensing and Czarnetzki, 1984; Chibana
et al., 2003; Eap et al., 2012). Fibroblasts are stimulated chemically
by inflammatory agents to differentiate into myofibroblasts that
have a greatly up-regulated rate of matrix production (discussed
in more detail below). In turn, fibroblasts produce and secrete
cytokines such as TGFβ1, IL-1β, IL-33, CXC, and CC chemokines
(Feghali and Wright, 1997; Gharaee-Kermani et al., 2003, 2012;
Scotton and Chambers, 2007), as well as reactive oxygen species
(Amara et al., 2010; Bondi et al., 2010). These factors allow fibrob-
lasts to assist in the activation and migration of resident immune
cells such as macrophages. Moreover, the recruitment of non-
resident immune cells is facilitated by the fibroblast-mediated
production and maintenance of the relatively spacious, non-solid
ground substance of the extracellular matrix, which plays an
important role as a thoroughfare for the extravasation of immune
cells into connective tissue. These tools endow fibroblast roles in
chemical (non-specific) and cell-mediated immunity, acute and
chronic inflammation, and inflammation resolution. Fibroblasts
can contribute to chronic inflammation (Flavell et al., 2008),
and reciprocally, inflammatory cytokines promote fibroblast to
myofibroblast transition, facilitating fibrosis.
ANGIOGENESIS
Fibroblasts have close interactions with endothelial cells and
facilitate angiogenesis into tissues beyond the reach of existing
blood vessels. This response requires the migration of endothe-
lial cells to construct tubes through the ground substance of
connective tissue (Dunn et al., 2000). Fibroblasts play a criti-
cal role in angiogenesis; fibroblast-derived matrix proteins and
cytokines are essential for endothelial cell-mediated lumen for-
mation (Newman et al., 2011). A major mechanism for this
phenomenon is the fibroblast-mediated production and release of
vascular endothelial growth factor (VEGF), which acts on VEGF
receptors expressed on endothelial cells to promote angiogene-
sis. Interestingly, dermal fibroblasts from SSc patients overexpress
VEGF in response to autocrine TGFβ signaling (Kajihara et al.,
2013). This VEGF could play a role in the vascular damage that in
turn promotes fibroblast activation, thereby supporting fibrosis
(Kajihara et al., 2013).
ANCILLARY SIGNALING FUNCTIONS OF FIBROBLASTS
The signaling factors associated with fibroblast biology are not
necessarily specific for one biological role over another. Below we
discuss these signaling factors with respect to their sources and
their cellular targets (Figure 1). The net effect of multiple stimuli
that recapitulate the milieu in human tissues is difficult to repro-
duce in the laboratory, although initial efforts using ex vivo organ
cultures such as skin (Yasuoka et al., 2008; Yamaguchi et al., 2012)
are promising.
PARACRINE SIGNALS THAT ACT ON FIBROBLASTS
Some factors act to promote a profibrotic phenotype. Platelet-
derived growth factor (PDGF) (Scotton and Chambers, 2007),
IL-6 (Feghali et al., 1992), IL-13 (Fuschiotti, 2011; Fuschiotti
et al., 2013), and the eicosanoid leukotrienes (Mensing and
Czarnetzki, 1984; Chibana et al., 2003; Eap et al., 2012) are
cytokines that promote inflammation and the development of a
fibrotic response. PDGF is produced by a variety of cell types,
such as platelets, endothelial cells, smooth muscle cells, and
macrophages. It acts on themesenchyme and fibroblasts to induce
proliferation, differentiation, and ECM production (Scotton and
Chambers, 2007). PDGF is important for wound healing, inflam-
mation, angiogenesis, embryonic development, and fibrosis. IL-6
is a pro-inflammatory cytokine that acts on a range of cell types
and is produced by T cells, macrophages, skeletal muscle cells,
and fibroblasts (Feghali and Wright, 1997). IL-6 has well-known
roles in inflammation, cellular differentiation, and fibrosis. IL-6
is elevated in the blood of SSc patients and produced in excess
by SSc fibroblasts (Feghali et al., 1992; Feghali and Wright, 1997).
Elevated IL-6 levels correlate with worse long-term survival, and
therefore IL-6 could potentially be used as a prognostic clinical
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FIGURE 1 | Overview of factors involved with the promotion of a profibrotic myofibroblast phenotype.
biomarker for patients with diseases such as SSc (Khan et al.,
2012). IL-13 is a cytokine mainly produced by mast cells but
also T lymphocytes (Wynn, 2003), and it acts on multiple cell
types, including fibroblasts. With roles in both inflammation and
fibrosis, IL-13 can stimulate TGFβ production, TGFβ activation,
collagen production, MMP expression, fibroblast proliferation,
and myofibroblast differentiation (Fuschiotti, 2011; Fuschiotti
et al., 2013). The leukotriene eicosanoids are additional signals
that induce fibroblast proliferation and matrix production con-
tributing to fibrosis (Mensing and Czarnetzki, 1984; Chibana
et al., 2003; Eap et al., 2012).
Of special note, the fibroblast growth factor (FGF) family
of genetically related protein ligands was originally identified
as mitogens and differentiation factors for fibroblasts (Armelin,
1973; Gospodarowicz, 1974). Despite the fact that this family
has since been found to act on multiple cell types, FGFs require
heparin or heparan sulfate proteoglycan molecules to bind their
surface receptors (Ornitz and Itoh, 2001). Therefore, they require
close proximity to ECM and the fibroblasts that secrete ECM.
There are 22 FGF genes found in humans (Ornitz and Itoh, 2001),
and these genes are alternatively-spliced (Ornitz and Itoh, 2001)
generating additional FGF proteins. FGF ligands activate a fam-
ily of 4 FGF receptors with differing specificities (Dionne et al.,
1991). High amounts of active FGF2 are found in bronchoalveolar
lavage fluid and in lung tissues of patients with pulmonary fibro-
sis (Henke et al., 1991; Inoue et al., 1996). Mast cell-generated
FGF2 correlates with the localization and the extent of fibrosis in
IPF (Inoue et al., 1996, 2002).
Paracrine factors that can antagonize fibrosis have also
been described. The eicosanoids prostaglandin E2 (PGE2)
(Keerthisingam et al., 2001; Maher et al., 2010) and prostacyclin
(PGI2) (Stratton et al., 2002) are two examples of paracrine sig-
nals that inhibit the fibrotic response. PGE2 inhibits fibroblast
proliferation and collagen production (McAnulty et al., 1997;
Goldstein and Polgar, 1982; Saltzman et al., 1982). It acts on target
cells by activating the G protein-coupled EP receptors 1–4. PGE2
has been observed to inhibit fibroblast to myofibroblast differen-
tiation and the TGFβ1 stimulated expression of α smooth muscle
actin (αSMA) in lung fibroblasts via the EP2 subtype receptors
(Kolodsick et al., 2003). PGE2 also has an anti-apoptotic effect on
the alveolar epithelium (Maher et al., 2010). Iloprost is a synthetic
analog of prostacyclin eicosanoid PGI2 that dilates systemic and
pulmonary arterial vascular beds and is used for the treatment of
patients with SSc (Erre and Passiu, 2009).
PARACRINE SIGNALS PRODUCED AND BROADCAST BY FIBROBLASTS
IGFBP-3 and -5, IGF-II, connective tissue growth factor (CTGF),
IL-33, CXC chemokines, CC chemokines, and reactive oxygen
species (ROS) are paracrine signals produced by fibroblasts that
further enhance a tissue fibrotic response. Both IGFBP-3 and -5
are profibrotic factors implicated in SSc and IPF (Veraldi et al.,
2009; Veraldi and Feghali-Bostwick, 2012). CTGF plays pivotal
roles in wound healing, angiogenesis, and fibrosis. It is highly
expressed by endothelial cells in response to a variety of stres-
sors, but it is also expressed and released by fibroblasts. CTGF
interacts with a wide variety of receptors, extracellular ligands,
as well as ECM proteins (Liu et al., 2011a). CTGF knock-out
mice are less responsive to the induction of fibrotic skin lesions
by bleomycin (Liu et al., 2011a). Conversely, transgenic mice
with fibroblast-specific expression of CTGF develop fibrosis with-
out any other profibrotic stimulus and display an accelerated
fibrotic response relative to exogenously added CTGF (Sonnylal
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et al., 2010). CTGF is well-characterized to act synergistically
with TGFβ to promote pathological fibrosis. Furthermore, TGFβ1
induces CTGF in fibroblasts (Leof et al., 1986; Paulsson et al.,
1987; Soma and Grotendorst, 1989; Igarashi et al., 1993; Mori
et al., 1999). IL-33 is a cytokine produced primarily by endothe-
lial and smooth muscle cells in the vasculature and the lungs.
However, its production by dermal fibroblasts can also be induced
by inflammation and in cardiac fibroblasts by mechanical stress.
Knocking down IL-33 expression in mice is cardioprotective in
the face of chronic angiotensin II stimulation (Sanada et al.,
2007). IL-33 facilitates inflammation and fibrosis (Savinko et al.,
2012). CXC and CC chemokines are broadcast by fibroblasts
and play significant roles in the chemotaxis of various leuko-
cytes to sites of tissue injury (Gharaee-Kermani et al., 2003,
2012). TGFβ also induces NADPH oxidase 4 (NOX4) in fibrob-
lasts (Amara et al., 2010; Bondi et al., 2010), implicating reactive
oxygen species (ROS) and oxidative stress in the pathology of
fibrosis. NOX4 generates a basal level of extracellular H2O2.
NOX4 mRNA expression is increased in rat kidney fibroblasts
in culture (Bondi et al., 2010) and in primary lung fibrob-
lasts derived from the lungs of patients with IPF (Amara et al.,
2010).
Fibroblasts do not typically express and release the angio-
genic hormone angiotensin II (AngII), however both activated
macrophages and myofibroblasts produce AngII during the
pathology of fibrosis (Berk et al., 2007). Although the phe-
nomenon is not well characterized inmost tissues, AngII is known
to promote TGFβ-mediated cardiac remodeling (Rosenkranz,
2004) and the fibrosis observed in left ventricular cardiac hyper-
trophy (Rosenkranz, 2004). These findings suggest that AngII
could contribute to fibrosis in other tissues.
AUTOCRINE ACTIONS AMONG FIBROBLASTS
TGFβ (Scotton and Chambers, 2007), IL-1β, and IL-6 (Feghali
and Wright, 1997) are examples of cytokines that are both pro-
duced by fibroblasts (as well as other cell types) and that act
on fibroblasts to promote inflammatory and fibrotic responses.
TGFβs are named after their ability to act on fibroblasts to induce
oncogenic transformation. The three known TGFβ ligands assert
their biological actions by activating TGFβ receptors, cell sur-
face serine/threonine kinase receptors. TGFβ is the prototypic
profibrotic cytokine. It acts on fibroblasts and myofibroblasts to
promote proliferation, migration, matrix production, the pro-
duction of chemotactic signals promoting leukocyte recruitment
to the site of injury, fibrosis, and the differentiation of fibroblasts
to myofibroblasts. Inhibitors of each TGFβ receptor antagonize
fibrosis development in experimental models (Bonniaud et al.,
2005; Fu et al., 2011). The cytokine IL-1β’s expression and release
is induced by a wide variety of cells, including fibroblasts, in
response to inflammation (Feghali and Wright, 1997). IL-1β is a
potent pro-inflammatory cytokine that also induces production
of the profibrotic cytokines PDGF and TGFβ.
Some autocrine fibroblast factors counteract fibrosis, such as
the hepatocyte growth factor (HGF). HGF is a protein produced
by fibroblasts and acts by binding the receptor tyrosine kinase
c-Met expressed on nearby epithelial cells, endothelial cells, and
fibroblasts (Bogatkevich et al., 2007a,b; Crestani et al., 2012).
HGF also plays an important role in wound healing, angiogenesis,
and tumorigenesis.
SOURCES OF FIBROBLASTS
Fibroblasts are a heterogeneous cell population that consists of
subsets with different capacities to produce ECM components
such as collagen. Fibroblast subpopulations have been described
in the skin (Jelaska and Korn, 2000) and lung (Pechkovsky et al.,
2010). Furthermore, fibroblast phenotypes may differ across sites
of the same organ, as has been shown in skin. In fact, fibroblasts
from different skin sites retain positional memory with dis-
tinct gene expression profiles (Chang et al., 2002). Furthermore,
fibroblasts are chemotactic and can migrate and accumulate in
new areas in response to secreted cytokines, a behavior well
characterized in the wound healing response after tissue injury.
Although the parenchyme of the liver, pancreas, and lung are
derived from endothelial tissue and the parenchyme of the skin
and brain are derived from epithelial tissue, the stromal connec-
tive tissue found in all organs is derived from mesothelial tissue.
Yet, due to the differing mixture of neighboring tissue types,
there is the potential for differential fibroblast phenotypes and
differential fibrotic responses in each of these organs.
Fibroblasts are not a terminally differentiated cell type and
retain the potential to be activated for differentiation into sub-
types of fibroblast-like cells. Myofibroblasts are rarely found in
healthy human physiology; they become vastly up-regulated after
injury and play a critical role in the wound healing response
(Gabbiani, 2003; Midwood et al., 2004). Myofibroblasts can orig-
inate from a variety of precursor cells, as shown in Figure 2.
Major developmental signaling factors such as the Wnt (Liu
et al., 2012), Notch (Kavian et al., 2012), and Sonic hedge-
hog ligands (Stewart et al., 2003; Ding et al., 2012) have well-
described roles in myofibroblast differentiation from precursor
cells. Myofibroblasts are well characterized to differentiate from
resident fibroblasts in vivo and in vitro in response to profi-
brotic cytokine stimulation. However, myofibroblasts have also
been observed to differentiate from various other precursor cells,
including epithelial cells, endothelial cells, pericytes, multipo-
tent monocytes, and fibrocytes. Whether different cell origins are
the source of myofibroblasts in different tissues remains to be
determined.
The myofibroblast phenotype is characterized as: (i) express-
ing αSMA; (ii) contractile; (iii) having a greater rate of ECM
synthesis and secretion; and (iv) resistant to apoptosis. The con-
tractile biology of myofibroblasts facilitates ECM fiber manipu-
lation and wound contraction at sites of injury. Myofibroblasts
display a heightened and constitutive expression of cytokines,
chemokines, and cell surface receptors (Strehlow and Korn, 1998;
Abraham and Varga, 2005). These differentiated myofibroblasts
also display epigenetic changes (Wang et al., 2006a).
EPITHELIAL CELLS
The EMT has been observed as a source of myofibroblasts in
kidney fibrosis (Ng et al., 1998; Jinde et al., 2001; Liu, 2004);
however, subsequent attempts to trace such phenomena in the
skin, lung, heart, and liver have been largely unsuccessful in vivo,
suggesting that EMT-mediated formation of myofibroblasts is
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FIGURE 2 | Myofibroblasts can differentiate from a variety of precursor cell types.
not substantial. Recent evidence argues against epithelial cells as
the main source of myofibroblast differentiation in idiopathic
lung fibrosis. Using lineage tracing with recombinant td-Tomato
and f-GFP tags and confocal microscopy resolution, Rock et al.
demonstrated focal accumulation of fibroblasts derived from the
proliferation of stromal cells (Rock et al., 2011). Recent trans-
genic lineage tracing studies in mouse kidney also indicate that
most myofibroblasts are not derived from epithelial cells (Lin
et al., 2008; Humphreys et al., 2010). Although these studies
using rodents contradict findings suggesting an epithelial origin
to myofibroblasts, they do not exclude the possibility that EMT
may occur in human tissues.
ENDOTHELIAL CELLS
Another source of myofibroblasts during fibrosis has been
hypothesized to originate from endothelial cells by a process of
endothelial-mesenchymal transition (EndoMT) (Piera-Velazquez
et al., 2011). This event has been characterized in animal mod-
els of fibrosis; however, similar phenomena in human fibrosis
patients have not yet been well characterized.
VASCULAR SMOOTH MUSCLE CELLS (VSMC)
The many similarities between myofibroblasts and VSMCs pro-
mote the question of a potential lineage relationship between
the two cell types (Yoshida and Owens, 2005). For example,
these cells are contractile and they share multiple markers such
as αSMA, SM22α, desmin, and vimentin (Yoshida and Owens,
2005). Furthermore, myofibroblasts express proteins, such as
osteopontin, that can be induced in VSMCs by phenotypicmodu-
lator ligands (Yoshida and Owens, 2005). However, the biological
roles of these two cell types in disease are different (Gan et al.,
2007). Furthermore, myofibroblasts and VSMCs have distinct
transcriptional mechanisms for αSMA expression (Gan et al.,
2007). Observations such as the induction of αSMA expres-
sion in myofibroblasts and the reduction in αSMA expression in
VSMCs during vascular injury (Yoshida and Owens, 2005) sug-
gest the reduction of a contractile phenotype in VSMCs could also
promote another source of myofibroblasts differentiation.
PERICYTES
Pericytes are mesenchyme-derived cells that wrap around small
blood vessel walls and closely associate with the outer surface of
the endothelial cell layer. Pericytes regulate the permeability of
the blood vessel wall; for example, pericytes are the principal cell
type that regulates the permeability of the blood–brain barrier
(Armulik et al., 2010). Pericytes physically interact with endothe-
lial cells and chemically via paracrine signaling to control the tight
junctions and transvessicular trafficking across endothelial cells.
As such, malfunctioning pericytes can promote vascular leaking
(Schrimpf et al., 2012), and the observation that perictyes can be
induced to differentiate into myofibroblasts, losing their pericyte
functionality, suggests that this differentiation may contribute to
both tissue fibrosis and vascular leakage in IPF (Hung et al., 2013).
Pericytes are not a terminally differentiated cell type; they can fur-
ther differentiate into fibroblasts, osteoblasts, and smooth muscle
cells. Pericytes endogenously express αSMA and have a function-
ing contractile apparatus; therefore, distinguishing between these
cells and other cell types is challenging. One genetic fate mapping
study investigating the potential contribution of pericytes in mice
to bleomycin-induced lung fibrosis utilized the nerve/glial anti-
gen 2 (NG2) protein, a chondroitin sulfate cell surface-associated
proteoglycan, as a marker for this cell type. This strategy found
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no appreciable contribution of pericytes to the expansion of
myofibroblasts and the resulting fibrosis even though the pericyte
population itself did expand significantly (Rock et al., 2011). A
different investigation utilized the forkhead transcription factor
Foxd1 as a marker for lung pericytes and found that up to 68%
of αSMA-expressing cells in fibrotic lungs are pericyte-derived
(Hung et al., 2013). These studies suggest that multiple sub-
populations of pericytes may exist in the lung and differentially
contribute to myofibroblast formation and fibrosis.
MONOCYTES AND FIBROCYTES
Fibrocytes are circulating fibroblast-like cells in the vascular sys-
tem that are derived from bone marrow stem cells (Bucala et al.,
1994). “Fibrocyte” is a term sometimes ascribed to a relatively
inactive fibroblast-like cell, whereas the term “fibroblast” des-
ignates a fully active cell as described throughout our review.
Fibrocytes can extravasate from vessels into connective tissues. In
the kidney, it has been proposed that myofibroblasts in fibrotic
areas could be derived from bone marrow progenitor multipotent
cells via a cellular differentiation lineage: bone marrow progeni-
tor cell to monocyte to fibrocyte to fibroblast (Quan et al., 2004;
Pilling and Gomer, 2012). Circulating CD14+ immunopheno-
typic monocytes derived from the plasma of SSc patients are
reported to express greater αSMA (and so an increased matura-
tion toward myofibroblasts) compared to those of healthy control
individuals but with minor functional contraction properties as
determined with a collagen contraction assay (Binai et al., 2012).
The blood of SSc patients with interstitial lung disease is enriched
for fibrocytes andmonocytes with an overt profibrotic phenotype
(Mathai et al., 2010). However, lineage tracing studies in rodents
display differing conclusions. GFP-expressing fibroblasts derived
from the multipotent, transgenic bone marrow transplanted into
chimeric normal mice appear to be a unique population of cells
that do not express αSMA and fail to differentiate into myofibrob-
lasts when extracted and stimulated ex vivo in culture (Hashimoto
et al., 2004; Kisseleva et al., 2006; Barisic-Dujmovic et al., 2010;
Rock et al., 2011). Similarly, using an αSMA promoter-driven
GFP transgenic mouse, no kidney or bone marrow stromal
expression was observed in chimeric wild-typemice (Yokota et al.,
2006). However, the chimeric mice were only analyzed under
physiologic conditions, and no profibrotic stimulus was tested in
this model (Yokota et al., 2006). In contrast, in another study,
bone marrow from GFP transgenic mice were transplanted into
wild-type rats, and a 23% increase in the number of GFP and
αSMA-expressing cells in the pancreas was observed to peak in the
early stage of an experimentally-induced but clinically-relevant
pancreatitis rat model (Mathai et al., 2010; Akita et al., 2012).
In all, despite substantial evidence that activated myofibroblasts
are derived from local stromal fibroblasts, blood borne mono-
cytes and monocyte-derived cells appear to facilitate fibrosis via
the production of ECM and paracrine signaling with resident
profibrotic cells (Murray et al., 2012).
ADVENTITIAL FIBROBLASTS IN PULMONARY
HYPERTENSION
A very similar role of fibroblast activation appears to promote
pulmonary hypertension compounding other fibrotic disorders.
Pulmonary hypertension can be a complication of IPF and SSc
and is a significant contributor to mortality (Lee et al., 1992;
Arcasoy et al., 2001; King et al., 2001). Adventitial fibroblasts
found in blood vessels can be activated by hypoxia and are impli-
cated as a source of myofibroblasts that promote vascular remod-
eling and the associated pulmonary hypertension (Stenmark
et al., 2006).
FIBROBLASTS IN CANCER BIOLOGY
Fibroblasts have an integral role in cancer beyond sarcomas
and cancers originating from fibroblastic cells. Non-cancerous
fibroblasts interact with cancer cells, affecting tumor biology
and pathogenesis. The biological processes of wound healing,
inflammation, fibrosis, angiogenesis, and their associated bio-
chemical machinery all play critical roles in cancer by regulating
the microenvironment of a tumor, tumor size, and tumor inva-
sion of adjacent tissues and metastasis (Mueller and Fusenig,
2004). Fibroblasts in and around tumors are persistently acti-
vated by tumor cells (Kalluri and Zeisberg, 2006). In response,
fibroblasts secrete cytokines and ECM that modulate tumor pro-
gression and regulate stroma-cancer interactions (Madar et al.,
2013). Non-cancerous fibroblasts surrounding tumors contribute
directly to angiogenesis and tumor growth by producing mul-
tifarious signaling molecules (Madar et al., 2013). Fibroblasts
also secrete the ECM that modulates tumor progression, and
fibroblasts remodel the connective tissue surrounding a tumor,
allowing cancerous cells to be released from a contained tumor
into the vascular system, thereby promoting metastasis (Liu et al.,
2011b). As such, fibroblast cells also participate in the pathogen-
esis of carcinomas—the more abundant cancers originating from
epithelial cells. In spite of recent advances in delineating the role
of fibroblasts in tumor progression, the role of these cells in earlier
tumor development is still incompletely understood.
POTENTIAL THERAPIES TARGETING FIBROBLASTS
Since fibroblasts are a central effector cell in fibrosis, they are
suitable therapeutic targets. There have been some recent excit-
ing research findings inciting potential strategies to combat the
pathological fibrotic response that occurs in various disorders.
The examples listed below are not intended to be a comprehen-
sive presentation for the pipeline of future antifibrotic therapies
that target the fibroblast cell lineage. There are multiple strategies
being investigated that are too numerous to cover here. The fol-
lowing examples help to illustrate the diverse range of targeting
strategies where novel therapies potentially could ensue.
ENDOSTATIN
Endostatin is an endogenous inhibitor of angiogenesis that has
completed clinical trials as an anticancer agent to prevent the
growth of tumor mass. It inhibits endothelial cell proliferation
and vessel formation (O’Reilly et al., 1997) but also acts on
fibroblasts (Yamaguchi et al., 2012). Endostatin is a small peptide
(20–30KDa) derived from the carboxy terminus of the collagen
type XVIII produced and released by fibroblasts. Endostatin is
then released from this precursor protein by proteolytic cleavage
by the action of cathepsin L (Felbor et al., 2000), and peptides of
differing lengths have also been reported to be generated by the
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matrix metalloproteases MMP-3, -7, -9, -13, or -20 (Heljasvaara
et al., 2005). Endostatin concentrations are greater in the blood
and lungs of patients with IPF and SSc, but these concentrations
do not seem to reach “therapeutic” levels (Hebbar et al., 2000;
Sumi et al., 2005; Richter et al., 2009). Interestingly, the amino ter-
minus portion of endostatin contains the anti-angiogenic func-
tionality (Tjin Tham Sjin et al., 2005), whereas the carboxy
terminus portion contains the antifibrotic activity, suggesting
that the two biological functions can be attributed to dissocia-
ble domains (Yamaguchi et al., 2012). Indeed, a 48 amino acid
portion of endostatin’s carboxy terminus has strong antifibrotic
actions in vitro, in vivo, and ex vivo in human tissue (Yamaguchi
et al., 2012). This peptide ameliorates pulmonary and dermal
fibrosis in an animal model and ex vivo in human skin in response
to TGFβ (Yamaguchi et al., 2012).
VITAMIN D3
Vitamin D is important for regulating mineral absorption in the
intestines, calcium and phosphate concentrations in blood, and
for maintaining bone integrity. However, vitamin D deficiency
has also been found to correlate with many extra-osseous disor-
ders. Vitamin D3 is processed by the liver to form the biologically
active form 1,25-dihydroxyvitamin D3 (1,25-(OH)2 vitamin D3).
1,25-(OH)2 vitamin D3 activates the vitamin D receptor (VDR,
a steroid hormone receptor) that heterodimerizes with retinoid
hormone receptor to directly regulate gene transcription. 1,25-
(OH)2 vitamin D3 inhibits the expression of type I collagen
in hepatic stellate cells (Potter et al., 2013). Furthermore, 1,25-
(OH)2 vitaminD3 has been observed to inhibit a fibrotic response
in human primary lung fibroblasts (Ramirez et al., 2010), and
1,25-(OH)2 vitamin D3 deficiency correlates with the severity of
liver fibrosis and that of SSc (Vacca et al., 2009; Caramaschi et al.,
2010; Rios Fernandez et al., 2010; Arnson et al., 2011; Slominski
et al., 2013). These studies suggest that the correction of vitamin
D deficiency is promising as a clinical strategy to alleviate fibrotic
disorders.
EPIGENETICS
Epigenetic changes in fibrosis are the subject of active investi-
gation. Several epigenetic modifications, like histone posttrans-
lational modifications and DNA methylation events, have been
reported. The fact that these epigenetic modifications do not alter
the DNA sequence suggests they are reversible, and as such, they
represent an attractive therapeutic strategy for countering fibro-
sis. Cyclooxygenase 2 (COX2) expression—a biosynthetic enzyme
for antifibrotic prostaglandin production—is suppressed in IPF
due to decreased histone acetylation (Coward et al., 2009), and
histone deacetylase 4 (HDAC4) activity mediates TGFβ stim-
ulated myofibroblast differentiation in a response that can be
inhibited by global inhibition of HDACs (Glenisson et al., 2007).
HDAC7 has been proposed as a potential target for the treat-
ment of SSc (Hemmatazad et al., 2009). DNA methylation of the
gene FLI1 coding for the ETS transcription factor Fli-1 inhibits its
genetic expression, resulting in enhanced collagen type 1 expres-
sion and persistent activation of fibroblasts in SSc (Wang et al.,
2006a). Primary fibroblasts isolated from the adventitial layer of
blood vessels following vascular injury maintain their activated,
pro-fibrotic state when grown in vitro (Li et al., 2011). The con-
stitutive activation is an imprinted phenotype maintained by
epigenetic alterations in key inflammatory and pro-fibrotic genes
(Li et al., 2011). Epigenetic drugs have been approved for cancer,
paving the way for using such agents, including DNA demethy-
lating agents, for other diseases. The reversibility of epigenetic
alterations and the ready availability of small molecule inhibitors
of these enzymes provide a potential future therapeutic strategy
that could antagonize the profibrotic phenotype of fibroblasts.
WNT-LIKE SIGNAL TRANSDUCTION PATHWAY
Wnt signaling and a classical Wnt-like intracellular signal trans-
duction pathway in fibrosis are a bustling area of research, and
multiple proteins within this pathway have been proposed as
druggable targets to prevent myofibroblast differentiation and
fibrosis. Wnt is a paradigm developmental signaling protein
that regulates proliferation, migration, and cell fate determina-
tion. Wnt ligands activate frizzled receptors—members of the G
protein-coupled receptor (GPCR) superfamily of proteins that
share common structure and function relationships—and pro-
mote the inhibition of glycogen synthase kinase 3β (GSK3β).
Interestingly, many other GPCRs such as the lysophosphatidic
acid receptor, the angiotensin type I receptor, the endothe-
lin 1 receptor, and CC and CXC chemokine receptors regu-
late myofibroblast differentiation and fibrosis. GPCRs have also
been demonstrated to couple to the Wnt-like intracellular sig-
nal transduction cascade Akt-GSK3β-βcatenin-PPARγ (Beaulieu
et al., 2004, 2005, 2008; Kendall et al., 2011). However, it is not
yet known if this cascade is the main contributor for GPCR-
regulation of myofibroblast transition and fibrosis. Regardless, it
is an interesting observation that multiple targets belonging to
this signaling pathway are currently being actively investigated as
potential targets for fibrosis therapies.
There is an apparent activation of the developmental Wnt-
βcatenin program in SSc (Bhattacharyya et al., 2012). Wnt acti-
vated βcatenin promotes fibroblast to myofibroblast transition in
human skin (Liu et al., 2012) and is required for TGFβ-mediated
fibrosis (Akhmetshina et al., 2012). While Akt is not required
for Wnt-stimulated catenin accumulation (Torres et al., 1999;
Chen et al., 2000), Akt has been implicated in sustaining the
Wnt signaling cascade (Fukumoto et al., 2001). Akt is a criti-
cal node of PI3K signaling and regulates cell cycle, cell growth,
and cell fate determination. PI3K-Akt signaling is also utilized
as a non-canonical pathway of TGF receptors that contribute to
fibrosis (Wan et al., 2013). Sustained Akt activation is critical for
upregulating αSMA expression and myofibroblast differentiation
in the wound healing response, implicating Akt as a potential
therapeutic target for fibrosis. Whereas a constitutively active
Akt1 protein (myr-Akt1) induces αSMA expression in fibrob-
lasts, a dominant negative Akt1 (Akt1 K179M) inhibits αSMA
expression (Abdalla et al., 2013). Akt is a ubiquitous kinase that
phosphorylates and inactivates the constitutive activity of GSK3β
(Fang et al., 2000). Knocking out GSK3β expression in fibroblasts
accelerates wound healing, increases fibrosis, enhances collagen
production, decreases cell apoptosis in wound sections, increases
profibrotic αSMA expression, and increases myofibroblast for-
mation (Kapoor et al., 2008). The transcriptional coregulator
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βcatenin is required for the TGFβ-mediated inhibition of per-
oxisome proliferator-activated receptor γ (PPARγ) expression in
hepatic stellate cells (Qian et al., 2012). PPARγ is a nuclear recep-
tor that is important for mesodermal cell fate determination.
PPARγ expression and activity promotes adipocyte differentia-
tion and inhibits fibroblast and hepatic stellate cell activation of
the profibrotic phenotype (Qian et al., 2012). PPARγ agonists
inhibit lung myofibroblast proliferation in vivo as well as TGFβ-
mediated myofibroblast differentiation and collagen production
in culture (Milam et al., 2008). PPARγ agonists also inhibit der-
mal fibrosis (Wei et al., 2010, 2012). Although only an associative
depiction of a pathway is characterized here from research on
individual proteins in this pathway, collectively they suggest that a
Wnt-like pathway could have a strong influence on myofibroblast
differentiation and fibrosis.
FIBROBLAST RECEPTORS
Caveolin 1 inhibits the function of the chemotactic receptor
CXCR4 in fibrocytes (Tourkina et al., 2011) and caveolin 1 is
down regulated in IPF (Wang et al., 2006b). The introduction
of a peptide containing the caveolin scaffolding domain of cave-
olin 1 is sufficient to inhibit fibrocyte accumulation in the lungs
in a bleomycin-induced animal model of fibrosis, suggesting that
the caveolin scaffolding domain could be employed as a poten-
tial therapy for SSc lung disease (Tourkina et al., 2011). In yet
another example, the single nucleotide polymorphism L412F in
the gene expressing Toll-like receptor 3 in pulmonary fibroblasts
has been found to correlate with a greater risk of mortality in
IPF patients (O’Dwyer et al., 2013). The L412F polymorphism
could be used as a biomarker for more progressive fibrotic dis-
ease, and the resulting loss of function of TLR3 is a potential
therapeutic target in IPF (O’Dwyer et al., 2013). This study high-
lights the importance of a personalized medicine approach to the
multifactorial group of fibrotic disorders. The inhibition of TLR4
has been reported to antagonize AngII-induced cardiac fibrosis
(Wang et al., 2014), the activity of TLR4 in hepatic stellate cells
enhances liver fibrosis (Seki et al., 2007), and the activity of TLR4
in skin fibroblasts enhances SSc (Bhattacharyya et al., 2013). Here,
the entanglement of inflammatory and ECM-producing func-
tions of fibroblasts can be exploited to improve fibrotic therapies
(Bhattacharyya et al., 2013).
Given the multifactorial etiology of various fibrotic disorders,
both in different tissues and within the same tissue (Murray et al.,
2012), the increasing interest in developing and employing per-
sonalized medicine, where a one-size-fits-all approach is unlikely
to be as effective, offers to accelerate the development of more
effective antifibrotic therapies for defined subsets of patients.
SUMMARY
Fibrosis is the thickening of ECM that is preceded by inflam-
mation or physical tissue injury. Fibroblasts are the principal
cell type that produces, maintains, and reabsorbs ECM. These
fibroblasts have the capacity to become activated by inflamma-
tory cytokines to myofibroblasts that display up-regulated cellular
migration, exaggerated ECM production, the endowment of a
contractile apparatus, and increased chemical signaling secretion
and responsiveness. Although various precursor cell types have
been observed to contribute to myofibroblast development, res-
ident fibroblast stromal cells appear to be the most significant
contributing source of myofibroblasts and the resulting tissue
fibrotic response in diseases such as SSc and IPF. Thus, fibroblasts
are a suitable therapeutic target. In view of the numerous fac-
tors at play in fibrosis, it is likely that combinatorial therapy that
includes targeting fibroblasts will be more effective than single
target approaches for the treatment of organ fibrosis.
ACKNOWLEDGMENT
Supported by K24 AR060297.
REFERENCES
Abdalla, M., Goc, A., Segar, L., and Somanath, P. R. (2013). Akt1 mediates
alpha-smooth muscle actin expression and myofibroblast differentiation via
myocardin and serum response factor. J. Biol. Chem. 288, 33483–33493. doi:
10.1074/jbc.M113.504290
Abraham, D. J., and Varga, J. (2005). Scleroderma: from cell and molec-
ular mechanisms to disease models. Trends Immunol. 26, 587–595. doi:
10.1016/j.it.2005.09.004
Akhmetshina, A., Palumbo, K., Dees, C., Bergmann, C., Venalis, P., Zerr, P.,
et al. (2012). Activation of canonical Wnt signalling is required for TGF-beta-
mediated fibrosis. Nat. Commun. 3, 735. doi: 10.1038/ncomms1734
Akita, S., Kubota, K., Kobayashi, A., Misawa, R., Shimizu, A., Nakata, T., et al.
(2012). Role of bone marrow cells in the development of pancreatic fibro-
sis in a rat model of pancreatitis induced by a choline-deficient/ethionine-
supplemented diet. Biochem. Biophys. Res. Commun. 420, 743–749. doi:
10.1016/j.bbrc.2012.03.060
Amara, N., Goven, D., Prost, F., Muloway, R., Crestani, B., and Boczkowski, J.
(2010). NOX4/NADPH oxidase expression is increased in pulmonary fibrob-
lasts from patients with idiopathic pulmonary fibrosis and mediates TGFbeta1-
induced fibroblast differentiation into myofibroblasts. Thorax 65, 733–738. doi:
10.1136/thx.2009.113456
Arcasoy, S. M., Christie, J. D., Pochettino, A., Rosengard, B. R., Blumenthal,
N. P., Bavaria, J. E., et al. (2001). Characteristics and outcomes of patients
with sarcoidosis listed for lung transplantation. Chest 120, 873–880. doi:
10.1378/chest.120.3.873
Armelin, H. A. (1973). Pituitary extracts and steroid hormones in the con-
trol of 3T3 cell growth. Proc. Natl. Acad. Sci. U.S.A. 70, 2702–2706. doi:
10.1073/pnas.70.9.2702
Armulik, A., Genove, G., Mae, M., Nisancioglu, M. H., Wallgard, E., Niaudet, C.,
et al. (2010). Pericytes regulate the blood-brain barrier. Nature 468, 557–561.
doi: 10.1038/nature09522
Arnson, Y., Amital, H., Agmon-Levin, N., Alon, D., Sanchez-Castanon, M., Lopez-
Hoyos, M., et al. (2011). Serum 25-OH vitamin D concentrations are linked
with various clinical aspects in patients with systemic sclerosis: a retrospective
cohort study and review of the literature. Autoimmun. Rev. 10, 490–494. doi:
10.1016/j.autrev.2011.02.002
Atanelishvili, I., Liang, J., Akter, T., Spyropoulos, D. D., Silver, R. M., and
Bogatkevich, G. S. (2014). Thrombin increases lung fibroblast survival while
promoting alveolar epithelial cell apoptosis via the endoplasmic reticulum stress
marker, CCAAT enhancer-binding homologous protein. Am. J. Respir. Cell Mol.
Biol. 50, 893–902. doi: 10.1165/rcmb.2013-0317OC
Barisic-Dujmovic, T., Boban, I., and Clark, S. H. (2010). Fibroblasts/myofibroblasts
that participate in cutaneous wound healing are not derived from circulating
progenitor cells. J. Cell. Physiol. 222, 703–712. doi: 10.1002/jcp.21997
Beaulieu, J. M., Marion, S., Rodriguiz, R. M., Medvedev, I. O., Sotnikova,
T. D., Ghisi, V., et al. (2008). A beta-arrestin 2 signaling complex medi-
ates lithium action on behavior. Cell 132, 125–136. doi: 10.1016/j.cell.2007.
11.041
Beaulieu, J. M., Sotnikova, T. D., Marion, S., Lefkowitz, R. J., Gainetdinov, R. R.,
and Caron,M. G. (2005). An Akt/beta-arrestin 2/PP2A signaling complexmedi-
ates dopaminergic neurotransmission and behavior. Cell 122, 261–273. doi:
10.1016/j.cell.2005.05.012
Beaulieu, J. M., Sotnikova, T. D., Yao, W. D., Kockeritz, L., Woodgett, J. R.,
Gainetdinov, R. R., et al. (2004). Lithium antagonizes dopamine-dependent
www.frontiersin.org May 2014 | Volume 5 | Article 123 | 9
Kendall and Feghali-Bostwick The roles of fibroblasts in fibrosis
behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cas-
cade. Proc. Natl. Acad. Sci. U.S.A. 101, 5099–5104. doi: 10.1073/pnas.03079
21101
Berk, B. C., Fujiwara, K., and Lehoux, S. (2007). ECM remodeling in hypertensive
heart disease. J. Clin. Invest. 117, 568–575. doi: 10.1172/JCI31044
Bhattacharyya, S., Kelley, K., Melichian, D. S., Tamaki, Z., Fang, F., Su, Y., et al.
(2013). Toll-like receptor 4 signaling augments transforming growth factor-
beta responses: a novel mechanism for maintaining and amplifying fibro-
sis in scleroderma. Am. J. Pathol. 182, 192–205. doi: 10.1016/j.ajpath.2012.
09.007
Bhattacharyya, S., Wei, J., Tourtellotte, W. G., Hinchcliff, M., Gottardi, C. G., and
Varga, J. (2012). Fibrosis in systemic sclerosis: common and unique patho-
biology. Fibrogenesis Tissue Repair 5(Suppl. 1):S18. doi: 10.1186/1755-1536-5-
S1-S18
Binai, N., O’Reilly, S., Griffiths, B., van Laar, J. M., and Hugle, T. (2012).
Differentiation potential of CD14+ monocytes into myofibroblasts in patients
with systemic sclerosis. PLoS ONE 7:e33508. doi: 10.1371/journal.pone.00
33508
Blaauboer, M. E., Boeijen, F. R., Emson, C. L., Turner, S. M., Zandieh-
Doulabi, B., Hanemaaijer, R., et al. (2013). Extracellular matrix proteins:
a positive feedback loop in lung fibrosis? Matrix Biol. 34, 170–178. doi:
10.1016/j.matbio.2013.11.002
Bogatkevich, G. S., Gustilo, E., Oates, J. C., Feghali-Bostwick, C., Harley, R. A.,
Silver, R. M., et al. (2005). Distinct PKC isoforms mediate cell survival and DNA
synthesis in thrombin-induced myofibroblasts. Am. J. Physiol. Lung Cell. Mol.
Physiol. 288, L190–L201. doi: 10.1152/ajplung.00448.2003
Bogatkevich, G. S., Ludwicka-Bradley, A., Highland, K. B., Hant, F., Nietert, P. J.,
Singleton, C. B., et al. (2007a). Impairment of the antifibrotic effect of hepato-
cyte growth factor in lung fibroblasts from African Americans: possible role in
systemic sclerosis. Arthritis Rheum. 56, 2432–2442. doi: 10.1002/art.22713
Bogatkevich, G. S., Ludwicka-Bradley, A., Highland, K. B., Hant, F., Nietert, P. J.,
Singleton, C. B., et al. (2007b). Down-regulation of collagen and connective
tissue growth factor expression with hepatocyte growth factor in lung fibroblasts
from white scleroderma patients via two signaling pathways. Arthritis Rheum.
56, 3468–3477. doi: 10.1002/art.22874
Bondi, C. D., Manickam, N., Lee, D. Y., Block, K., Gorin, Y., Abboud, H. E., et al.
(2010). NAD(P)H oxidase mediates TGF-beta1-induced activation of kidney
myofibroblasts. J. Am. Soc. Nephrol. 21, 93–102. doi: 10.1681/ASN.2009020146
Bonniaud, P., Margetts, P. J., Kolb, M., Schroeder, J. A., Kapoun, A. M., Damm,
D., et al. (2005). Progressive transforming growth factor beta1-induced lung
fibrosis is blocked by an orally active ALK5 kinase inhibitor. Am. J. Respir. Crit.
Care Med. 171, 889–898. doi: 10.1164/rccm.200405-612OC
Brissett, M., Veraldi, K. L., Pilewski, J. M., Medsger, T. A. Jr., and Feghali-Bostwick,
C. A. (2012). Localized expression of tenascin in systemic sclerosis-associated
pulmonary fibrosis and its regulation by insulin-like growth factor binding
protein 3. Arthritis Rheum. 64, 272–280. doi: 10.1002/art.30647
Bucala, R., Spiegel, L. A., Chesney, J., Hogan, M., and Cerami, A. (1994).
Circulating fibrocytes define a new leukocyte subpopulation thatmediates tissue
repair.Mol. Med. 1, 71–81.
Caramaschi, P., Dalla Gassa, A., Ruzzenente, O., Volpe, A., Ravagnani, V., Tinazzi,
I., et al. (2010). Very low levels of vitamin D in systemic sclerosis patients. Clin.
Rheumatol. 29, 1419–1425. doi: 10.1007/s10067-010-1478-3
Chang, H. Y., Chi, J. T., Dudoit, S., Bondre, C., van de Rijn, M., Botstein,
D., et al. (2002). Diversity, topographic differentiation, and positional mem-
ory in human fibroblasts. Proc. Natl. Acad. Sci. U.S.A. 99, 12877–12882. doi:
10.1073/pnas.162488599
Chen, R. H., Ding, W. V., and McCormick, F. (2000). Wnt signaling to beta-catenin
involves two interactive components. Glycogen synthase kinase-3beta inhibi-
tion and activation of protein kinase C. J. Biol. Chem. 275, 17894–17899. doi:
10.1074/jbc.M905336199
Chibana, K., Ishii, Y., Asakura, T., and Fukuda, T. (2003). Up-regulation of cys-
teinyl leukotriene 1 receptor by IL-13 enables human lung fibroblasts to respond
to leukotriene C4 and produce eotaxin. J. Immunol. 170, 4290–4295. doi:
10.4049/jimmunol.170.8.4290
Chung, C. Y., Zardi, L., and Erickson, H. P. (1995). Binding of tenascin-C to
soluble fibronectin and matrix fibrils. J. Biol. Chem. 270, 29012–29017. doi:
10.1074/jbc.270.48.29012
Coward, W. R., Watts, K., Feghali-Bostwick, C. A., Knox, A., and Pang, L. (2009).
Defective histone acetylation is responsible for the diminished expression
of cyclooxygenase 2 in idiopathic pulmonary fibrosis. Mol. Cell. Biol. 29,
4325–4339. doi: 10.1128/MCB.01776-08
Cox, T. R., Bird, D., Baker, A. M., Barker, H. E., Ho, M. W., Lang, G., et al. (2013).
LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metas-
tasis. Cancer Res. 73, 1721–1732. doi: 10.1158/0008-5472.CAN-12-2233
Crestani, B., Marchand-Adam, S., Quesnel, C., Plantier, L., Borensztajn, K.,
Marchal, J., et al. (2012). Hepatocyte growth factor and lung fibrosis. Proc. Am.
Thorac. Soc. 9, 158–163. doi: 10.1513/pats.201202-018AW
De Laporte, L., Rice, J. J., Tortelli, F., and Hubbell, J. A. (2013). Tenascin C promis-
cuously binds growth factors via its fifth fibronectin type III-like domain. PLoS
ONE 8:e62076. doi: 10.1371/journal.pone.0062076
Ding, H., Zhou, D., Hao, S., Zhou, L., He, W., Nie, J., et al. (2012). Sonic
hedgehog signaling mediates epithelial-mesenchymal communication and pro-
motes renal fibrosis. J. Am. Soc. Nephrol. 23, 801–813. doi: 10.1681/ASN.2011
060614
Dionne, C. A., Jaye, M., and Schlessinger, J. (1991). Structural diversity and binding
of FGF receptors. Ann. N. Y. Acad. Sci. 638, 161–166. doi: 10.1111/j.1749-
6632.1991.tb49026.x
Dunn, I. F., Heese, O., and Black, P. M. (2000). Growth factors in glioma
angiogenesis: FGFs, PDGF, EGF, and TGFs. J. Neurooncol. 50, 121–137. doi:
10.1023/A:1006436624862
Eap, R., Jacques, E., Semlali, A., Plante, S., and Chakir, J. (2012). Cysteinyl
leukotrienes regulate TGF-beta(1) and collagen production by bronchial fibrob-
lasts obtained from asthmatic subjects. Prostaglandins Leukot. Essent. Fatty Acids
86, 127–133. doi: 10.1016/j.plefa.2011.11.001
Erre, G. L., and Passiu, G. (2009). Antioxidant effect of Iloprost: current knowledge
and therapeutic implications for systemic sclerosis. Reumatismo 61, 90–97. doi:
10.4081/reumatismo.2009.90
Fang, X., Yu, S. X., Lu, Y., Bast, R. C., Woodgett, J. R., and Mills, G. B.
(2000). Phosphorylation and inactivation of glycogen synthase kinase 3
by protein kinase A. Proc. Natl. Acad. Sci. U.S.A. 97, 11960–11965. doi:
10.1073/pnas.220413597
Feghali, C. A., Bost, K. L., Boulware, D. W., and Levy, L. S. (1992). Mechanisms of
pathogenesis in scleroderma. I. Overproduction of interleukin 6 by fibroblasts
cultured from affected skin sites of patients with scleroderma. J. Rheumatol. 19,
1207–1211.
Feghali, C. A., andWright, T. M. (1997). Cytokines in acute and chronic inflamma-
tion. Front. Biosci. 2, d12–d26.
Felbor, U., Dreier, L., Bryant, R. A., Ploegh, H. L., Olsen, B. R., and Mothes, W.
(2000). Secreted cathepsin L generates endostatin from collagen XVIII. EMBO
J. 19, 1187–1194. doi: 10.1093/emboj/19.6.1187
Flavell, S. J., Hou, T. Z., Lax, S., Filer, A. D., Salmon, M., and Buckley, C. D.
(2008). Fibroblasts as novel therapeutic targets in chronic inflammation. Br. J.
Pharmacol. 153(Suppl. 1), S241–S246. doi: 10.1038/sj.bjp.0707487
Fu, R., Wu, J., Ding, J., Sheng, J., Hong, L., Sun, Q., et al. (2011). Targeting trans-
forming growth factor betaRII expression inhibits the activation of hepatic
stellate cells and reduces collagen synthesis. Exp. Biol. Med. (Maywood) 236,
291–297. doi: 10.1258/ebm.2010.010231
Fukumoto, S., Hsieh, C. M., Maemura, K., Layne, M. D., Yet, S. F., Lee, K. H., et al.
(2001). Akt participation in the Wnt signaling pathway through Dishevelled.
J. Biol. Chem. 276, 17479–17483. doi: 10.1074/jbc.C000880200
Fuschiotti, P. (2011). Role of IL-13 in systemic sclerosis. Cytokine 56, 544–549. doi:
10.1016/j.cyto.2011.08.030
Fuschiotti, P., Larregina, A. T., Ho, J., Feghali-Bostwick, C., and Medsger, T.
A. Jr. (2013). Interleukin-13-producing CD8+ T cells mediate dermal fibro-
sis in patients with systemic sclerosis. Arthritis Rheum. 65, 236–246. doi:
10.1002/art.37706
Gabbiani, G. (2003). The myofibroblast in wound healing and fibrocontractive
diseases. J. Pathol. 200, 500–503. doi: 10.1002/path.1427
Gan, Q., Yoshida, T., Li, J., and Owens, G. K. (2007). Smooth mus-
cle cells and myofibroblasts use distinct transcriptional mechanisms for
smooth muscle alpha-actin expression. Circ. Res. 101, 883–892. doi:
10.1161/CIRCRESAHA.107.154831
Gharaee-Kermani, M., Kasina, S., Moore, B. B., Thomas, D., Mehra, R., and
Macoska, J. A. (2012). CXC-type chemokines promote myofibroblast phe-
noconversion and prostatic fibrosis. PLoS ONE 7:e49278. doi: 10.1371/jour-
nal.pone.0049278
Gharaee-Kermani, M., McCullumsmith, R. E., Charo, I. F., Kunkel, S. L., and Phan,
S. H. (2003). CC-chemokine receptor 2 required for bleomycin-induced
Frontiers in Pharmacology | Inflammation Pharmacology May 2014 | Volume 5 | Article 123 | 10
Kendall and Feghali-Bostwick The roles of fibroblasts in fibrosis
pulmonary fibrosis. Cytokine 24, 266–276. doi: 10.1016/j.cyto.2003.
08.003
Gilbane, A. J., Denton, C. P., and Holmes, A. M. (2013). Scleroderma pathogenesis:
a pivotal role for fibroblasts as effector cells. Arthritis Res. Ther. 15, 215. doi:
10.1186/ar4230
Glenisson, W., Castronovo, V., and Waltregny, D. (2007). Histone deacetylase
4 is required for TGFbeta1-induced myofibroblastic differentiation. Biochim.
Biophys. Acta 1773, 1572–1582. doi: 10.1016/j.bbamcr.2007.05.016
Goldstein, R. H., and Polgar, P. (1982). The effect and interaction of bradykinin and
prostaglandins on protein and collagen production by lung fibroblasts. J. Biol.
Chem. 257, 8630–8633.
Gospodarowicz, D. (1974). Localisation of a fibroblast growth factor and its effect
alone and with hydrocortisone on 3T3 cell growth. Nature 249, 123–127. doi:
10.1038/249123a0
Hashimoto, N., Jin, H., Liu, T., Chensue, S. W., and Phan, S. H. (2004). Bone
marrow-derived progenitor cells in pulmonary fibrosis. J. Clin. Invest. 113,
243–252. doi: 10.1172/JCI200418847
Hebbar, M., Peyrat, J. P., Hornez, L., Hatron, P. Y., Hachulla, E., and Devulder,
B. (2000). Increased concentrations of the circulating angiogenesis inhibitor
endostatin in patients with systemic sclerosis. Arthritis Rheum. 43, 889–893. doi:
10.1002/1529-0131(200004)43:4<889::AID-ANR21>3.0.CO;2-5
Heljasvaara, R., Nyberg, P., Luostarinen, J., Parikka, M., Heikkila, P., Rehn, M., et al.
(2005). Generation of biologically active endostatin fragments from human col-
lagen XVIII by distinct matrixmetalloproteases. Exp. Cell Res. 307, 292–304. doi:
10.1016/j.yexcr.2005.03.021
Hemmatazad, H., Rodrigues, H. M., Maurer, B., Brentano, F., Pileckyte, M., Distler,
J. H., et al. (2009). Histone deacetylase 7, a potential target for the antifi-
brotic treatment of systemic sclerosis. Arthritis Rheum. 60, 1519–1529. doi:
10.1002/art.24494
Henke, C., Fiegel, V., Peterson, M., Wick, M., Knighton, D., McCarthy, J., et al.
(1991). Identification and partial characterization of angiogenesis bioactivity in
the lower respiratory tract after acute lung injury. J. Clin. Invest. 88, 1386–1395.
doi: 10.1172/JCI115445
Howell, D. C., Johns, R. H., Lasky, J. A., Shan, B., Scotton, C. J., Laurent, G. J., et al.
(2005). Absence of proteinase-activated receptor-1 signaling affords protection
from bleomycin-induced lung inflammation and fibrosis. Am. J. Pathol. 166,
1353–1365. doi: 10.1016/S0002-9440(10)62354-1
Hoyles, R. K., Derrett-Smith, E. C., Khan, K., Shiwen, X., Howat, S. L., Wells, A.
U., et al. (2011). An essential role for resident fibroblasts in experimental lung
fibrosis is defined by lineage-specific deletion of high-affinity type II transform-
ing growth factor beta receptor. Am. J. Respir. Crit. Care Med. 183, 249–261. doi:
10.1164/rccm.201002-0279OC
Humphreys, B. D., Lin, S. L., Kobayashi, A., Hudson, T. E., Nowlin, B. T.,
Bonventre, J. V., et al. (2010). Fate tracing reveals the pericyte and not epithe-
lial origin of myofibroblasts in kidney fibrosis. Am. J. Pathol. 176, 85–97. doi:
10.2353/ajpath.2010.090517
Hung, C., Linn, G., Chow, Y. H., Kobayashi, A., Mittelsteadt, K., Altemeier, W. A.,
et al. (2013). Role of lung pericytes and resident fibroblasts in the pathogen-
esis of pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 188, 820–830. doi:
10.1164/rccm.201212-2297OC
Igarashi, A., Okochi, H., Bradham, D. M., and Grotendorst, G. R. (1993).
Regulation of connective tissue growth factor gene expression in human
skin fibroblasts and during wound repair. Mol. Biol. Cell 4, 637–645. doi:
10.1091/mbc.4.6.637
Inoue, Y., King, T. E. Jr., Barker, E., Daniloff, E., and Newman, L. S. (2002). Basic
fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and
lymphangioleiomyomatosis. Am. J. Respir. Crit. Care Med. 166, 765–773. doi:
10.1164/rccm.2010014
Inoue, Y., King, T. E. Jr., Tinkle, S. S., Dockstader, K., and Newman, L. S. (1996).
Human mast cell basic fibroblast growth factor in pulmonary fibrotic disorders.
Am. J. Pathol. 149, 2037–2054.
Jelaska, A., and Korn, J. H. (2000). Role of apoptosis and transforming growth fac-
tor beta1 in fibroblast selection and activation in systemic sclerosis. Arthritis
Rheum. 43, 2230–2239. doi: 10.1002/1529-0131(200010)43:10<2230::AID-
ANR10>3.0.CO;2-8
Jinde, K., Nikolic-Paterson, D. J., Huang, X. R., Sakai, H., Kurokawa, K., Atkins,
R. C., et al. (2001). Tubular phenotypic change in progressive tubulointersti-
tial fibrosis in human glomerulonephritis. Am. J. Kidney Dis. 38, 761–769. doi:
10.1053/ajkd.2001.27693
Kajihara, I., Jinnin, M., Honda, N., Makino, K., Makino, T., Masuguchi, S.,
et al. (2013). Scleroderma dermal fibroblasts overexpress vascular endothelial
growth factor due to autocrine transforming growth factor beta signaling.Mod.
Rheumatol. 23, 516–524. doi: 10.3109/s10165-012-0698-6
Kalluri, R., and Zeisberg, M. (2006). Fibroblasts in cancer. Nat. Rev. Cancer 6,
392–401. doi: 10.1038/nrc1877
Kapoor, M., Liu, S., Shi-wen, X., Huh, K., McCann, M., Denton, C. P., et al. (2008).
GSK-3beta in mouse fibroblasts controls wound healing and fibrosis through
an endothelin-1-dependent mechanism. J. Clin. Invest. 118, 3279–3290. doi:
10.1172/JCI35381R1
Kavian, N., Servettaz, A., Weill, B., and Batteux, F. (2012). New insights into the
mechanism of notch signalling in fibrosis. Open Rheumatol. J. 6, 96–102. doi:
10.2174/1874312901206010096
Kawelke, N., Vasel, M., Sens, C., Au, A., Dooley, S., and Nakchbandi, I. A. (2011).
Fibronectin protects from excessive liver fibrosis by modulating the availability
of and responsiveness of stellate cells to active TGF-beta. PLoS ONE 6:e28181.
doi: 10.1371/journal.pone.0028181
Keerthisingam, C. B., Jenkins, R. G., Harrison, N. K., Hernandez-Rodriguez,
N. A., Booth, H., Laurent, G. J., et al. (2001). Cyclooxygenase-2 deficiency
results in a loss of the anti-proliferative response to transforming growth
factor-beta in human fibrotic lung fibroblasts and promotes bleomycin-induced
pulmonary fibrosis in mice. Am. J. Pathol. 158, 1411–1422. doi: 10.1016/S0002-
9440(10)64092-8
Kendall, R. T., Strungs, E. G., Rachidi, S. M., Lee, M. H., El-Shewy, H. M., Luttrell,
D. K., et al. (2011). The beta-arrestin pathway-selective type 1A angiotensin
receptor (AT1A) agonist [Sar1,Ile4,Ile8]angiotensin II regulates a robust G
protein-independent signaling network. J. Biol. Chem. 286, 19880–19891. doi:
10.1074/jbc.M111.233080
Khan, K., Xu, S., Nihtyanova, S., Derrett-Smith, E., Abraham, D., Denton,
C. P., et al. (2012). Clinical and pathological significance of interleukin 6
overexpression in systemic sclerosis. Ann. Rheum. Dis. 71, 1235–1242. doi:
10.1136/annrheumdis-2011-200955
King, T. E. Jr., Tooze, J. A., Schwarz, M. I., Brown, K. R., and Cherniack, R.
M. (2001). Predicting survival in idiopathic pulmonary fibrosis: scoring sys-
tem and survival model. Am. J. Respir. Crit. Care Med. 164, 1171–1181. doi:
10.1164/ajrccm.164.7.2003140
Kisseleva, T., Uchinami, H., Feirt, N., Quintana-Bustamante, O., Segovia, J.
C., Schwabe, R. F., et al. (2006). Bone marrow-derived fibrocytes par-
ticipate in pathogenesis of liver fibrosis. J. Hepatol. 45, 429–438. doi:
10.1016/j.jhep.2006.04.014
Kolb, M., Margetts, P. J., Galt, T., Sime, P. J., Xing, Z., Schmidt, M., et al. (2001).
Transient transgene expression of decorin in the lung reduces the fibrotic
response to bleomycin. Am. J. Respir. Crit. Care Med. 163, 770–777. doi:
10.1164/ajrccm.163.3.2006084
Kolodsick, J. E., Peters-Golden, M., Larios, J., Toews, G. B., Thannickal, V. J.,
and Moore, B. B. (2003). Prostaglandin E2 inhibits fibroblast to myofibrob-
last transition via E. prostanoid receptor 2 signaling and cyclic adenosine
monophosphate elevation. Am. J. Respir. Cell Mol. Biol. 29, 537–544. doi:
10.1165/rcmb.2002-0243OC
Lee, P., Langevitz, P., Alderdice, C. A., Aubrey, M., Baer, P. A., Baron, M.,
et al. (1992). Mortality in systemic sclerosis (scleroderma). Q. J. Med. 82,
139–148.
Leof, E. B., Proper, J. A., Goustin, A. S., Shipley, G. D., DiCorleto, P. E., and Moses,
H. L. (1986). Induction of c-sis mRNA and activity similar to platelet-derived
growth factor by transforming growth factor beta: a proposed model for indi-
rect mitogenesis involving autocrine activity. Proc. Natl. Acad. Sci. U.S.A. 83,
2453–2457. doi: 10.1073/pnas.83.8.2453
Li, M., Riddle, S. R., Frid, M. G., El Kasmi, K. C., McKinsey, T. A., Sokol, R. J.,
et al. (2011). Emergence of fibroblasts with a proinflammatory epigenetically
altered phenotype in severe hypoxic pulmonary hypertension. J. Immunol. 187,
2711–2722. doi: 10.4049/jimmunol.1100479
Lin, S. L., Kisseleva, T., Brenner, D. A., and Duffield, J. S. (2008). Pericytes and
perivascular fibroblasts are the primary source of collagen-producing cells
in obstructive fibrosis of the kidney. Am. J. Pathol. 173, 1617–1627. doi:
10.2353/ajpath.2008.080433
Liu, J., Wang, Y., Pan, Q., Su, Y., Zhang, Z., Han, J., et al. (2012). Wnt/beta-catenin
pathway forms a negative feedback loop during TGF-beta1 induced human nor-
mal skin fibroblast-to-myofibroblast transition. J. Dermatol. Sci. 65, 38–49. doi:
10.1016/j.jdermsci.2011.09.012
www.frontiersin.org May 2014 | Volume 5 | Article 123 | 11
Kendall and Feghali-Bostwick The roles of fibroblasts in fibrosis
Liu, M., Xu, J., and Deng, H. (2011b). Tangled fibroblasts in tumor-stroma
interactions. Int. J. Cancer 129, 1795–1805. doi: 10.1002/ijc.26116
Liu, S., Shi-wen, X., Abraham, D. J., and Leask, A. (2011a). CCN2 is required for
bleomycin-induced skin fibrosis in mice. Arthritis Rheum. 63, 239–246. doi:
10.1002/art.30074
Liu, Y. (2004). Epithelial to mesenchymal transition in renal fibrogenesis: patho-
logic significance, molecular mechanism, and therapeutic intervention. J. Am.
Soc. Nephrol. 15, 1–12. doi: 10.1097/01.ASN.0000106015.29070.E7
Madar, S., Goldstein, I., and Rotter, V. (2013). “Cancer associated
fibroblasts”–more than meets the eye. Trends Mol. Med. 19, 447–453. doi:
10.1016/j.molmed.2013.05.004
Maher, T. M., Evans, I. C., Bottoms, S. E., Mercer, P. F., Thorley, A. J., Nicholson,
A. G., et al. (2010). Diminished prostaglandin E2 contributes to the apoptosis
paradox in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 182,
73–82. doi: 10.1164/rccm.200905-0674OC
Mathai, S. K., Gulati, M., Peng, X., Russell, T. R., Shaw, A. C., Rubinowitz, A. N.,
et al. (2010). Circulating monocytes from systemic sclerosis patients with inter-
stitial lung disease show an enhanced profibrotic phenotype. Lab. Invest. 90,
812–823. doi: 10.1038/labinvest.2010.73
McAnulty, R. J., Hernandez-Rodriguez, N. A., Mutsaers, S. E., Coker, R. K., and
Laurent, G. J. (1997). Indomethacin suppresses the anti-proliferative effects of
transforming growth factor-beta isoforms on fibroblast cell cultures. Biochem.
J. 321(Pt 3), 639–643.
McKleroy, W., Lee, T. H., and Atabai, K. (2013). Always cleave up your mess: target-
ing collagen degradation to treat tissue fibrosis. Am. J. Physiol. Lung Cell. Mol.
Physiol. 304, L709–L721. doi: 10.1152/ajplung.00418.2012
Mensing, H., and Czarnetzki, B. M. (1984). Leukotriene B4 induces in vitro
fibroblast chemotaxis. J. Invest. Dermatol. 82, 9–12. doi: 10.1111/1523-
1747.ep12258678
Midwood, K., Sacre, S., Piccinini, A.M., Inglis, J., Trebaul, A., Chan, E., et al. (2009).
Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for
maintaining inflammation in arthritic joint disease.Nat. Med. 15, 774–780. doi:
10.1038/nm.1987
Midwood, K. S., Williams, L. V., and Schwarzbauer, J. E. (2004). Tissue repair
and the dynamics of the extracellular matrix. Int. J. Biochem. Cell Biol. 36,
1031–1037. doi: 10.1016/j.biocel.2003.12.003
Milam, J. E., Keshamouni, V. G., Phan, S. H., Hu, B., Gangireddy, S. R.,
Hogaboam, C. M., et al. (2008). PPAR-gamma agonists inhibit profibrotic
phenotypes in human lung fibroblasts and bleomycin-induced pulmonary
fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 294, L891–L901. doi:
10.1152/ajplung.00333.2007
Mori, T., Kawara, S., Shinozaki, M., Hayashi, N., Kakinuma, T., Igarashi, A., et al.
(1999). Role and interaction of connective tissue growth factor with transform-
ing growth factor-beta in persistent fibrosis: a mouse fibrosis model. J. Cell.
Physiol. 181, 153–159. doi: 10.1002/(SICI)1097-4652(199910)181:1<153::AID-
JCP16>3.0.CO;2-K
Mueller, M. M., and Fusenig, N. E. (2004). Friends or foes—bipolar effects of
the tumour stroma in cancer. Nat. Rev. Cancer 4, 839–849. doi: 10.1038/
nrc1477
Murray, L. A., Rubinowitz, A., and Herzog, E. L. (2012). Interstitial lung disease:
is interstitial lung disease the same as scleroderma lung disease? Curr. Opin.
Rheumatol. 24, 656–662. doi: 10.1097/BOR.0b013e3283588de4
Newman, A. C., Nakatsu, M. N., Chou, W., Gershon, P. D., and Hughes, C.
C. (2011). The requirement for fibroblasts in angiogenesis: fibroblast-derived
matrix proteins are essential for endothelial cell lumen formation. Mol. Biol.
Cell 22, 3791–3800. doi: 10.1091/mbc.E11-05-0393
Ng, Y. Y., Huang, T. P., Yang, W. C., Chen, Z. P., Yang, A. H., Mu, W., et al. (1998).
Tubular epithelial-myofibroblast transdifferentiation in progressive tubuloin-
terstitial fibrosis in 5/6 nephrectomized rats. Kidney Int. 54, 864–876. doi:
10.1046/j.1523-1755.1998.00076.x
O’Dwyer, D. N., Armstrong, M. E., Trujillo, G., Cooke, G., Keane, M. P., Fallon,
P. G., et al. (2013). The Toll-like receptor 3 L412F polymorphism and disease
progression in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 188,
1442–1450. doi: 10.1164/rccm.201304-0760OC
O’Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., et al. (1997).
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell
88, 277–285. doi: 10.1016/S0092-8674(00)81848-6
Ornitz, D. M., and Itoh, N. (2001). Fibroblast growth factors. Genome Biol. 2:3005.
doi: 10.1186/gb-2001-2-3-reviews3005
Paulsson, Y., Hammacher, A., Heldin, C. H., and Westermark, B. (1987). Possible
positive autocrine feedback in the prereplicative phase of human fibroblasts.
Nature 328, 715–717. doi: 10.1038/328715a0
Pearson, C. A., Pearson, D., Shibahara, S., Hofsteenge, J., and Chiquet-Ehrismann,
R. (1988). Tenascin: cDNA cloning and induction by TGF-beta. EMBO J. 7,
2977–2982.
Pechkovsky, D. V., Hackett, T. L., An, S. S., Shaheen, F., Murray, L. A., and Knight,
D. A. (2010). Human lung parenchyma but not proximal bronchi produces
fibroblasts with enhanced TGF-beta signaling and alpha-SMA expression. Am.
J. Respir. Cell Mol. Biol. 43, 641–651. doi: 10.1165/rcmb.2009-0318OC
Piera-Velazquez, S., Li, Z., and Jimenez, S. A. (2011). Role of endothelial-
mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders.
Am. J. Pathol. 179, 1074–1080. doi: 10.1016/j.ajpath.2011.06.001
Pilling, D., and Gomer, R. H. (2012). Differentiation of circulating monocytes into
fibroblast-like cells.MethodsMol. Biol. 904, 191–206. doi: 10.1007/978-1-61779-
943-3_16
Potter, J. J., Liu, X., Koteish, A., and Mezey, E. (2013). 1,25-dihydroxyvitamin D3
and its nuclear receptor repress human alpha1 (I) collagen expression and type
I collagen formation. Liver Int. 33, 677–686. doi: 10.1111/liv.12122
Qian, J., Niu, M., Zhai, X., Zhou, Q., and Zhou, Y. (2012). beta-Catenin pathway is
required for TGF-beta1 inhibition of PPARgamma expression in cultured hep-
atic stellate cells. Pharmacol. Res. 66, 219–225. doi: 10.1016/j.phrs.2012.06.003
Quan, T. E., Cowper, S., Wu, S. P., Bockenstedt, L. K., and Bucala, R. (2004).
Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int. J.
Biochem. Cell Biol. 36, 598–606. doi: 10.1016/j.biocel.2003.10.005
Ramirez, A. M., Wongtrakool, C., Welch, T., Steinmeyer, A., Zugel, U., and Roman,
J. (2010). Vitamin D inhibition of pro-fibrotic effects of transforming growth
factor beta1 in lung fibroblasts and epithelial cells. J. Steroid Biochem. Mol. Biol.
118, 142–150. doi: 10.1016/j.jsbmb.2009.11.004
Richter, A. G., McKeown, S., Rathinam, S., Harper, L., Rajesh, P., McAuley, D.
F., et al. (2009). Soluble endostatin is a novel inhibitor of epithelial repair
in idiopathic pulmonary fibrosis. Thorax 64, 156–161. doi: 10.1136/thx.2008.
102814
Rios Fernandez, R., Fernandez Roldan, C., Callejas Rubio, J. L., and Ortego
Centeno, N. (2010). Vitamin D deficiency in a cohort of patients with systemic
scleroderma from the south of Spain. J. Rheumatol. 37, 1355; author reply 1356.
doi: 10.3899/jrheum.091143
Rock, J. R., Barkauskas, C. E., Cronce, M. J., Xue, Y., Harris, J. R., Liang, J., et al.
(2011). Multiple stromal populations contribute to pulmonary fibrosis without
evidence for epithelial to mesenchymal transition. Proc. Natl. Acad. Sci. U.S.A.
108, E1475–E1483. doi: 10.1073/pnas.1117988108
Rosenkranz, S. (2004). TGF-beta1 and angiotensin networking in cardiac remodel-
ing. Cardiovasc. Res. 63, 423–432. doi: 10.1016/j.cardiores.2004.04.030
Ruiz, X. D., Mlakar, L. R., Yamaguchi, Y., Su, Y., Larregina, A. T., Pilewski, J.
M., et al. (2012). Syndecan-2 is a novel target of insulin-like growth factor
binding protein-3 and is over-expressed in fibrosis. PLoS ONE 7:e43049. doi:
10.1371/journal.pone.0043049
Saltzman, L. E., Moss, J., Berg, R. A., Hom, B., and Crystal, R. G. (1982).
Modulation of collagen production by fibroblasts. Effects of chronic exposure
to agonists that increase intracellular cyclic AMP. Biochem. J. 204, 25–30.
Sanada, S., Hakuno, D., Higgins, L. J., Schreiter, E. R., McKenzie, A. N., and
Lee, R. T. (2007). IL-33 and ST2 comprise a critical biomechanically induced
and cardioprotective signaling system. J. Clin. Invest. 117, 1538–1549. doi:
10.1172/JCI30634
Santos, V. N., Leite-Mor, M. M., Kondo, M., Martins, J. R., Nader, H., Lanzoni,
V. P., et al. (2005). Serum laminin, type IV collagen and hyaluronan as fibrosis
markers in non-alcoholic fatty liver disease. Braz. J. Med. Biol. Res. 38, 747–753.
doi: 10.1590/S0100-879X2005000500012
Savinko, T., Matikainen, S., Saarialho-Kere, U., Lehto, M., Wang, G., Lehtimaki,
S., et al. (2012). IL-33 and ST2 in atopic dermatitis: expression profiles and
modulation by triggering factors. J. Invest. Dermatol. 132, 1392–1400. doi:
10.1038/jid.2011.446
Schnapp, L. M., Hatch, N., Ramos, D. M., Klimanskaya, I. V., Sheppard, D., and
Pytela, R. (1995). The human integrin alpha 8 beta 1 functions as a receptor
for tenascin, fibronectin, and vitronectin. J. Biol. Chem. 270, 23196–23202. doi:
10.1074/jbc.270.39.23196
Schrimpf, C., Xin, C., Campanholle, G., Gill, S. E., Stallcup, W., Lin, S. L., et al.
(2012). Pericyte TIMP3 and ADAMTS1 modulate vascular stability after kidney
injury. J. Am. Soc. Nephrol. 23, 868–883. doi: 10.1681/ASN.2011080851
Frontiers in Pharmacology | Inflammation Pharmacology May 2014 | Volume 5 | Article 123 | 12
Kendall and Feghali-Bostwick The roles of fibroblasts in fibrosis
Scotton, C. J., and Chambers, R. C. (2007). Molecular targets in pulmonary
fibrosis: the myofibroblast in focus. Chest 132, 1311–1321. doi: 10.1378/chest.
06-2568
Seki, E., De Minicis, S., Osterreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A.,
et al. (2007). TLR4 enhances TGF-beta signaling and hepatic fibrosis.Nat. Med.
13, 1324–1332. doi: 10.1038/nm1663
Slominski, A., Janjetovic, Z., Tuckey, R. C., Nguyen, M. N., Bhattacharya, K.
G., Wang, J., et al. (2013). 20S-hydroxyvitamin D3, noncalcemic product of
CYP11A1 action on vitamin D3, exhibits potent antifibrogenic activity in vivo.
J. Clin. Endocrinol. Metabol. 98, E298–E303. doi: 10.1210/jc.2012-3074
Soma, Y., and Grotendorst, G. R. (1989). TGF-beta stimulates primary human skin
fibroblast DNA synthesis via an autocrine production of PDGF-related peptides.
J. Cell. Physiol. 140, 246–253. doi: 10.1002/jcp.1041400209
Sonnylal, S., Shi-Wen, X., Leoni, P., Naff, K., Van Pelt, C. S., Nakamura, H., et al.
(2010). Selective expression of connective tissue growth factor in fibroblasts
in vivo promotes systemic tissue fibrosis. Arthritis Rheum. 62, 1523–1532. doi:
10.1002/art.27382
Stenmark, K. R., Fagan, K. A., and Frid, M. G. (2006). Hypoxia-induced pulmonary
vascular remodeling: cellular andmolecularmechanisms.Circ. Res. 99, 675–691.
doi: 10.1161/01.RES.0000243584.45145.3f
Stewart, G. A., Hoyne, G. F., Ahmad, S. A., Jarman, E., Wallace, W. A., Harrison,
D. J., et al. (2003). Expression of the developmental Sonic hedgehog (Shh) sig-
nalling pathway is up-regulated in chronic lung fibrosis and the Shh receptor
patched 1 is present in circulating T lymphocytes. J. Pathol. 199, 488–495. doi:
10.1002/path.1295
Stratton, R., Rajkumar, V., Ponticos, M., Nichols, B., Shiwen, X., Black, C. M.,
et al. (2002). Prostacyclin derivatives prevent the fibrotic response to TGF-
beta by inhibiting the Ras/MEK/ERK pathway. FASEB J. 16, 1949–1951. doi:
10.1096/fj.02-0204fje
Strehlow, D., and Korn, J. H. (1998). Biology of the scleroderma fibroblast. Curr.
Opin. Rheumatol. 10, 572–578. doi: 10.1097/00002281-199811000-00011
Sumi, M., Satoh, H., Kagohashi, K., Ishikawa, H., and Sekizawa, K. (2005).
Increased serum levels of endostatin in patients with idiopathic pulmonary
fibrosis. J. Clin. Lab. Anal. 19, 146–149. doi: 10.1002/jcla.20069
Tjin Tham Sjin, R. M., Satchi-Fainaro, R., Birsner, A. E., Ramanujam, V. M.,
Folkman, J., and Javaherian, K. (2005). A 27-amino-acid synthetic peptide cor-
responding to the NH2-terminal zinc-binding domain of endostatin is respon-
sible for its antitumor activity. Cancer Res. 65, 3656–3663. doi: 10.1158/0008-
5472.CAN-04-1833
Torres, M. A., Eldar-Finkelman, H., Krebs, E. G., and Moon, R. T. (1999).
Regulation of ribosomal S6 protein kinase-p90(rsk), glycogen synthase kinase 3,
and beta-catenin in early Xenopus development.Mol. Cell. Biol. 19, 1427–1437.
Tourkina, E., Bonner, M., Oates, J., Hofbauer, A., Richard, M., Znoyko, S., et al.
(2011). Altered monocyte and fibrocyte phenotype and function in scleroderma
interstitial lung disease: reversal by caveolin-1 scaffolding domain peptide.
Fibrogenesis Tissue Repair 4:15. doi: 10.1186/1755-1536-4-15
Vacca, A., Cormier, C., Piras, M., Mathieu, A., Kahan, A., and Allanore, Y.
(2009). Vitamin D deficiency and insufficiency in 2 independent cohorts
of patients with systemic sclerosis. J. Rheumatol. 36, 1924–1929. doi:
10.3899/jrheum.081287
Veraldi, K. L., and Feghali-Bostwick, C. A. (2012). Insulin-like growth
factor binding proteins-3 and -5: central mediators of fibrosis and
promising new therapeutic targets. Open Rheumatol. J. 6, 140–145. doi:
10.2174/1874312901206010140
Veraldi, K. L., Gibson, B. T., Yasuoka, H., Myerburg, M. M., Kelly, E. A., Balzar,
S., et al. (2009). Role of insulin-like growth factor binding protein-3 in aller-
gic airway remodeling. Am. J. Respir. Crit. Care Med. 180, 611–617. doi:
10.1164/rccm.200810-1555OC
Wan, Y. Y., Tian, G. Y., Guo, H. S., Kang, Y. M., Yao, Z. H., Li, X. L., et al.
(2013). Endostatin, an angiogenesis inhibitor, ameliorates bleomycin-induced
pulmonary fibrosis in rats. Respir. Res. 14:56. doi: 10.1186/1465-9921-14-56
Wang, L., Li, Y. L., Zhang, C. C., Cui, W., Wang, X., Xia, Y., et al. (2014). Inhibition
of Toll-like receptor 2 reduces cardiac fibrosis by attenuating macrophage-
mediated inflammation. Cardiovasc. Res. 101, 383–392. doi: 10.1093/cvr/cvt258
Wang, X. M., Zhang, Y., Kim, H. P., Zhou, Z., Feghali-Bostwick, C. A., Liu, F., et al.
(2006b). Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary
fibrosis. J. Exp. Med. 203, 2895–2906. doi: 10.1084/jem.20061536
Wang, Y., Fan, P. S., and Kahaleh, B. (2006a). Association between enhanced type
I collagen expression and epigenetic repression of the FLI1 gene in scleroderma
fibroblasts. Arthritis Rheum. 54, 2271–2279. doi: 10.1002/art.21948
Wei, J., Bhattacharyya, S., Jain, M., and Varga, J. (2012). Regulation of matrix
remodeling by peroxisome proliferator-activated receptor-gamma: a novel link
between metabolism and fibrogenesis. Open Rheumatol. J. 6, 103–115. doi:
10.2174/1874312901206010103
Wei, J., Bhattacharyya, S., and Varga, J. (2010). Peroxisome proliferator-activated
receptor gamma: innate protection from excessive fibrogenesis and potential
therapeutic target in systemic sclerosis.Curr. Opin. Rheumatol. 22, 671–676. doi:
10.1097/BOR.0b013e32833de1a7
Wynn, T. A. (2003). IL-13 effector functions. Annu. Rev. Immunol. 21, 425–456.
doi: 10.1146/annurev.immunol.21.120601.141142
Yamaguchi, Y., Mann, D. M., and Ruoslahti, E. (1990). Negative regulation of trans-
forming growth factor-beta by the proteoglycan decorin. Nature 346, 281–284.
doi: 10.1038/346281a0
Yamaguchi, Y., Takihara, T., Chambers, R. A., Veraldi, K. L., Larregina, A. T., and
Feghali-Bostwick, C. A. (2012). A peptide derived from endostatin ameliorates
organ fibrosis. Sci. Trans. Med. 4, 136ra171. doi: 10.1126/scitranslmed.3003421
Yasuoka, H., Larregina, A. T., Yamaguchi, Y., and Feghali-Bostwick, C. A. (2008).
Human skin culture as an ex vivo model for assessing the fibrotic effects of
insulin-like growth factor binding proteins. Open Rheumatol. J. 2, 17–22. doi:
10.2174/1874312900802010017
Yokota, T., Kawakami, Y., Nagai, Y., Ma, J. X., Tsai, J. Y., Kincade, P. W., et al. (2006).
Bone marrow lacks a transplantable progenitor for smooth muscle type alpha-
actin-expressing cells. Stem Cells 24, 13–22. doi: 10.1634/stemcells.2004-0346
Yoshida, T., and Owens, G. K. (2005). Molecular determinants of vas-
cular smooth muscle cell diversity. Circ. Res. 96, 280–291. doi:
10.1161/01.RES.0000155951.62152.2e
Yu, W. H., and Woessner, J. F. Jr. (2000). Heparan sulfate proteoglycans as extra-
cellular docking molecules for matrilysin (matrix metalloproteinase 7). J. Biol.
Chem. 275, 4183–4191. doi: 10.1074/jbc.275.6.4183
Yu, W. H., Yu, S., Meng, Q., Brew, K., and Woessner, J. F. Jr. (2000). TIMP-3 binds
to sulfated glycosaminoglycans of the extracellular matrix. J. Biol. Chem. 275,
31226–31232. doi: 10.1074/jbc.M000907200
Zeisberg, M., Bonner, G., Maeshima, Y., Colorado, P., Muller, G. A., Strutz, F.,
et al. (2001). Renal fibrosis: collagen composition and assembly regulates
epithelial-mesenchymal transdifferentiation. Am. J. Pathol. 159, 1313–1321.
doi: 10.1016/S0002-9440(10)62518-7
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Received: 19 March 2014; accepted: 09 May 2014; published online: 27 May 2014.
Citation: Kendall RT and Feghali-Bostwick CA (2014) Fibroblasts in fibrosis: novel
roles and mediators. Front. Pharmacol. 5:123. doi: 10.3389/fphar.2014.00123
This article was submitted to Inflammation Pharmacology, a section of the journal
Frontiers in Pharmacology.
Copyright © 2014 Kendall and Feghali-Bostwick. This is an open-access article dis-
tributed under the terms of the Creative Commons Attribution License (CC BY). The
use, distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this jour-
nal is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
www.frontiersin.org May 2014 | Volume 5 | Article 123 | 13
